Skip to main content
. Author manuscript; available in PMC: 2017 Sep 8.
Published in final edited form as: Cancer Causes Control. 2016 Mar 21;27(5):627–636. doi: 10.1007/s10552-016-0736-3

Table 1. Clinicopathological Characteristics of Breast Cancer Patients (n=416) in the NCI-SEER Connecticut Tumor Registry (2000-07).

White n =214 AA/B n=202 P-Value1

TNBC
ER- PR- HER2- 35 (16.4) 52 (25.7)
Non-TNBC <0.01
ER- PR- HER2+ 6 (2.8) 20 (9.9)
ER/PR+ HER2- 143 (66.8) 117 (57.9)
ER/PR+ HER2+ 30 (14.0) 13 (6.4)

Vital Status
Alive 166 (77.6) 133 (65.8) <0.01
Dead 48 (22.4) 69 (34.2)
Median follow-up time (Among Alive)3 9.7 yrs 10.3 yrs 0.22

Cause of Death
Breast Cancer 21 (43.8) 35 (50.7)
Other Cancer 8 (16.7) 8 (11.6) 0.81
CVD 6 (12.5) 7 (10.1)
Other 13 (27.1) 19 (27.5)

Histological Sub-Type
Ductal 124 (57.9) 127 (62.9)
Lobular 24 (11.2) 12 (5.9) 0.04
Mixed Ductal/Lobular 52 (24.3) 37 (18.3)
Other 14 (6.5) 26 (12.9)

Tumor Grade
I 25 (12.1) 22 (11.5)
II 93 (45.1) 73 (38.2) 0.04
III/IV 88 (42.7) 96 (50.3)

Tumor Size, Mean (SD) 2.07 cm (1.5) 2.26 cm (1.6) 0.22

Positive Axillary Nodes,4 Mean (SD) 3.35 (3.9) 6.67 (16.3) 0.11

SEER Summary Stage
Local 145 (67.8) 119 (58.9)
Regional 66 (30.8) 73 (36.1) 0.04
Distant 3 (1.4) 10 (5.0)

First-Course Chemotherapy5 (Yes)
Local 42 (32.3) 41 (39.4) 0.27
Regional 47 (75.8) 50 (73.5) 0.84
1

Chi-square test for categorical data and independent t-test for continuous variables

2

n (%) except where noted

3

Non-parametric Test of Medians

4

Among patients with Regional Summary Stage (n=63 White; n=66 AA/B)

5

Too few patients with Distant disease (n=12) to perform reliable analyses